How do you fight an activist investor breathing down your neck? By getting another large investor on your side. Fighting fire with fire, if you will.
Carl Icahn's chances to join the board of Genzyme
In January, Genzyme struck a deal with Whitworth, offering a board seat this November in exchange for Whitworth's support of the company's nominees at the upcoming shareholder meeting. I guess Genzyme didn't think that was enough to win shareholders' support and decided to give Whitworth a seat on the board now, along with being allowed to approve the nomination of another independent director.
Whitworth will chair a new Strategic Planning and Capital Allocation Committee. You'll recall that Genzyme's failures and the reason why investors big and small are upset with the company have to do with its manufacturing plants. A contamination and a separate issue with filling drug vials have led shares to fall 37% from their high in 2008.
Interestingly, according to The Wall Street Journal, Whitworth tried to act as an intermediary between Icahn and Genzyme and offered to propose a director amenable to both sides, but Icahn refused because he wanted more seats. The continued pressure from Icahn appears to have led to the expanded power for Whitworth.
Icahn looks to be losing the battle, assuming the new outside leadership is enough to persuade investors to stick with management for another year. But he may have won the war.
Sometimes it's necessary for activist investors to take over the board as Icahn did with ImClone Systems, eventually getting Eli Lilly
Turnarounds can be tough, and only time will tell if Whitworth plus Genzyme can get the job done. But whether they succeed or fail, it's clear that Icahn got the ball rolling.
More from The Motley Fool
3 Stocks Stopping the Presses
What do the latest big headlines from these companies mean for you?
The Timing of This Move Seems Quite Suspect
What's the real motivation behind Carl Icahn's sudden largesse -- and could it affect your portfolio?
With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche
The field might benefit from the increased interest in it among pharmaceutical players.